GLP 1
Breaking a True Plateau: Evidence-Ranked Interventions
Introduction The fastest way to break a plateau is usually not a new intervention at all: it’s a 7-day measurement audit, because most stalls…
Body Recomposition on GLP-1: Losing Fat, Keeping Muscle
Introduction Body recomposition on a GLP-1 drug means losing fat while keeping the muscle you have, so your body changes shape and composition even…
Body Image Lag: When the Mirror Catches up to the Scale
Body image lag is the gap between how much your body has changed and how slowly your self-perception catches up.
Bimagrumab vs Exercise for Muscle Retention on GLP-1
Introduction Bimagrumab versus exercise for muscle retention is a comparison worth making carefully, because one side is proven and available while the other is…
Bimagrumab Timeline: When Could It Reach Patients?
Introduction The bimagrumab timeline can be stated honestly in one line: it is years from patients, with large phase 3 trials still required and…
Bimagrumab Side Effects and Safety Signals From Trials
Introduction Bimagrumab’s side effect profile is notably different from the GLP-1 drugs most people associate with weight loss, and understanding why starts with its…
Bimagrumab Plus GLP-1: The Body Recomposition Combo Trials
Introduction The bimagrumab plus GLP-1 combination is one of the most strategically interesting ideas in obesity medicine because it tackles a problem the blockbuster…
Bimagrumab Complete Guide: Muscle-Preserving Antibody Explained
Introduction Bimagrumab is one of the most mechanistically interesting drugs in the obesity pipeline because it does something most weight-loss drugs do not: it…
CalPERS to Walmart: Big Employers’ GLP-1 Decisions Tracked
Introduction Big employers’ GLP-1 decisions are worth tracking for a simple reason: when a plan covering hundreds of thousands of lives says yes, no,…